Depressivnye rasstroystva v praktike psikhiatra i nevrologa
- Authors: Magomedova A.N1, Azimova Y.E1
-
Affiliations:
- Issue: No 19 (2013)
- Pages: 10-15
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286430
- ID: 286430
Cite item
Open Access
Access granted
Abstract
Depressive disorders are characterized by significant clinical polymorphism and can occured in the practice of any medical specialists. The course of depressive disorders and the selection of antidepressants in neurological diseases have their own features. Selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors are the drugs of choice in the treatment of depression in neurological diseases.
Keywords
Full Text
References
- Barak Y., Plopski I., Tadger S., Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study // Int. Psychogeriatr. - 2011. - Vol. 23. -P. 1515-19.
- Ensrud K.E., Joffe H., Guthrie K.A., et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial // Menopause. -2012. - Vol. 19. - P. 848-55.
- Frances A. DSM-5 somatic symptom disorder // J. Nerv. Ment. Dis. - 2013. - Vol. 201. -P. 530-31.
- Kanner A.M. Epilepsy, depression and anxiety disorders: a complex relation with significant therapeutic implications for the three conditions // J. Neurol. Neurosurg. Psychiatry. - 2013. -Vol. 84. - e1.
- Mikami K., Jorge R.E., Moser D.J., et al. Prevention of poststroke apathy using escitalopram or problem-solving therapy // Am. J. Geriatr. Psychiatry. - 2013. - Vol. 21. -P. 855-62.
- Mitsonis C.I., Zervas I.M., Potagas C.M., et al. Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study // Eur. Neuropsychopharmacol. - 2010. - Vol. 20. - P. 123-31.
- Murakami T., Hama S., Yamashita H., et al. Neuroanatomic pathways associated with poststroke affective and apathetic depression // Am. J. Geriatr. Psychiatry. - 2013. - Vol. 21. -P. 840-47.
- Radat F., Creac'h C., Swendsen J.D., et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache // Cephalalgia. - 2005. - Vol. 25. - P. 519-22.
- Richard E., Reitz C., Honig L.H., et al. Late-life depression, mild cognitive impairment, and dementia //JAMA. Neurol. - 2013. - Vol. 70. -P. 374-82.
- Rocha F.F., Carneiro J.G., Pereira Pde A., et al. Poststroke manic symptoms: an unusual neuropsychiatric condition // Rev. Bras. Psiquiatr. - 2008. - Vol. 30. - P. 173-74.
- Thase M.E., Larsen K.G., Reines E., et al. The cardiovascular safety profile of escitalopram // Eur. Neuropsychopharmacol. - 2013. - Vol. 5. -S0924-977.
- Trillo L., Das D., Hsieh W., et al. Ascending mono-aminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care //Neurosci. Biobehav. Rev. - 2013. - Vol. 37. -P. 1363-79.
- Vos T., Flaxman A., Naghavi M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 // Lancet. - 2012. - Vol. 380. -P. 2163-96.
- Weintraub D., Taraborelli D., Morales K.H., et al. Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study// J. Neuropsychiatry Clin. Neurosci. - 2006. -Vol. 18. - P. 377-83.
Supplementary files
